Key Highlights
- Reports indicate Eli Lilly is close to finalizing an acquisition of Kelonia Therapeutics valued at more than $2 billion
- An official announcement may come as soon as Monday, with possible additional milestone-linked payments
- Kelonia specializes in next-generation CAR-T treatment targeting multiple myeloma, a type of blood cancer
- The Boston biotech firm has secured nearly $60 million in funding and carried a valuation slightly above $100 million in 2022
- This acquisition would strengthen Lilly’s cancer drug portfolio as it diversifies beyond its obesity medication franchise
Pharmaceutical powerhouse Eli Lilly is moving toward finalizing a deal to purchase Boston-based Kelonia Therapeutics for a sum exceeding $2 billion, the Wall Street Journal disclosed on Sunday. Sources suggest an announcement could materialize as soon as Monday, though the negotiations remain fluid and could potentially collapse.
According to individuals briefed on the discussions, the agreement may incorporate supplementary payments contingent upon Kelonia achieving specific clinical and regulatory milestones, the Journal indicated.
Shares of LLY climbed approximately 2.55% following the disclosure.
Kelonia operates as a clinical-stage biotechnology company specializing in CAR-T cellular immunotherapies — innovative treatments that engineer a patient’s immune system cells to identify and eliminate malignant cells.
The firm’s primary research centers on multiple myeloma, a blood cancer affecting plasma cells. Kelonia’s proprietary methodology seeks to streamline CAR-T administration by eliminating chemotherapy requirements and the intricate cell-processing procedures traditionally associated with these treatments.
This represents a significant advancement in the CAR-T domain, where treatment accessibility and manufacturing challenges have historically limited broader adoption.
To date, Kelonia has secured funding totaling just under $60 million. The company’s most recent valuation stood marginally above $100 million in 2022 — rendering the reported $2 billion-plus acquisition price a substantial premium.
Neither Eli Lilly nor Kelonia provided responses to Reuters’ inquiries for comment outside standard business hours.
Expanding the Oncology Franchise
Lilly maintains an established presence in cancer therapeutics. Its current oncology portfolio features Jaypirca and the breast cancer medication Verzenio, alongside several investigational compounds in development.
Acquiring Kelonia would accelerate Lilly’s expansion into hematologic malignancies, representing one of oncology’s most rapidly advancing therapeutic areas.
This transaction aligns with recent strategic activity. Lilly has pursued aggressive deal-making, supported by robust revenue generation from its highly successful obesity drug Zepbound and diabetes medication Mounjaro.
This past February, Lilly announced plans to purchase Orna Therapeutics in a transaction valued at up to $2.4 billion. The Kelonia acquisition would mark another substantial investment within a compressed timeframe.
Strategic Diversification Beyond Metabolic Disease
Lilly has openly communicated its diversification objectives. The pharmaceutical company has systematically expanded into inflammatory bowel conditions, ophthalmic disorders, oncology, and gene-editing platforms through strategic acquisitions and collaborative partnerships.
CAR-T immunotherapies align precisely with this strategic vision. The technology has demonstrated substantial efficacy in treating hematologic cancers, with multiple therapies already receiving regulatory approval — though manufacturing complexity and treatment costs continue to present significant industry obstacles.
Kelonia’s streamlined treatment paradigm represents its primary appeal. If the company can generate comparable clinical outcomes with reduced logistical complications, that constitutes a meaningful competitive advantage warranting premium valuation.
Lilly has not officially validated the transaction. The Wall Street Journal noted that negotiations could still dissolve before any formal announcement.
LLY stock registered gains of roughly 2.55% in response to the reporting.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
